A medication that prevents dangerous pressure spikes in the eye during laser procedures just became much more accessible to patients. The FDA-approved drug IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) has been assigned a permanent billing code by the Centers for Medicare and Medicaid Services (CMS), meaning insurance will now reimburse doctors for administering it in their offices starting July 1, 2026 . This regulatory change removes a major barrier that had prevented many eye doctors from routinely using the medication, even though it's been proven effective for decades.

What Problem Does This Drug Actually Solve?

When eye doctors perform certain laser procedures to treat glaucoma and other eye conditions, patients face a real risk of intraocular pressure (IOP) spikes, which are sudden, dangerous increases in the pressure inside the eye. These spikes can cause immediate symptoms like severe eye pain, blurred vision, and nausea. In vulnerable patients, they can even lead to optic nerve damage that threatens vision . IOPIDINE 1% is the only FDA-approved medication specifically designed to prevent these pressure spikes from happening in the first place.

The drug's track record is impressive. When doctors give patients IOPIDINE 1% before and immediately after laser procedures, it reduces severe pressure spikes from approximately 23% in untreated patients down to approximately 2%, representing a roughly 91% relative risk reduction . That's a dramatic difference in patient safety and comfort during a procedure that more than 1.5 million Americans undergo annually in the United States .

Why Couldn't Doctors Use This Drug Before If It Works So Well?

The answer comes down to insurance billing. Before this week's announcement, IOPIDINE 1% didn't have a permanent J-Code, which is the CMS billing designation that allows physicians to be reimbursed directly for drugs they administer in their offices. Without this code, doctors had to absorb the cost of the medication themselves or navigate complicated workarounds, making it economically impractical to use routinely . Even though the drug was FDA-approved and effective, the administrative and financial friction meant many patients never received it, even when they were at high risk for complications.

Now that the permanent J-Code (J2374) has been issued, that friction disappears. Doctors can administer IOPIDINE 1% at the time of the procedure and get reimbursed by insurance, making it both clinically and economically sensible to use it as standard care .

Which Eye Procedures Benefit From This Drug?

IOPIDINE 1% is indicated for several types of in-office laser procedures that eye doctors perform to treat glaucoma and other conditions. These procedures include:

• Selective Laser Trabeculoplasty (SLT): A laser treatment that helps fluid drain from the eye to lower pressure in glaucoma patients.
• Argon Laser Trabeculoplasty (ALT): An older laser technique that works similarly to SLT by improving fluid drainage.
• Laser Peripheral Iridotomy (LPI): A procedure that creates a small opening in the iris to improve fluid flow and prevent angle-closure glaucoma.
• Nd:YAG Capsulotomy: A laser procedure used to treat clouding of the lens capsule that can occur after cataract surgery.
• Argon Laser Iridotomy: An alternative to LPI using argon laser technology.

As the population ages and early intervention becomes more standard practice, the number of these procedures continues to grow, meaning more patients will potentially benefit from this preventive approach .

What Do Eye Care Professionals Say About This Change?

Eye doctors across different specialties have expressed enthusiasm about having reimbursed access to this medication. The change addresses a real gap in their ability to protect patients during procedures.

"Optometrists are the front-line physicians diagnosing and managing glaucoma in the United States, and increasingly, performing laser procedures such as YAGs, SLTs, and LPIs. I am thrilled to now have reimbursed access to an on-label therapy to best ensure my patients are protected from intraocular pressure spikes," said Dr. Ben Gaddie, OD.

Dr. Ben Gaddie, OD

Glaucoma specialists also see this as a game-changer for patient care and communication. Having a reimbursed option means doctors can address the risk of pressure spikes in real time while counseling patients about the importance of controlling their eye pressure, which can improve how patients understand and follow their treatment plans .

"When I can administer a proven pressure-lowering therapy immediately following a procedure, especially for high-risk patients, it's a game-changer for my practice protocols. It gives both the physician and the patient confidence that we're starting from a position of control, not uncertainty," explained Dr. Kyle Linsey, DO, Cataract and Refractive Surgeon.

Dr. Kyle Linsey, DO, Cataract and Refractive Surgeon

How to Prepare for an In-Office Laser Eye Procedure

If you're scheduled for an in-office laser procedure to treat glaucoma or another eye condition, here are key steps to take:

• Ask Your Doctor About Pressure Spike Prevention: When you schedule your procedure, specifically ask your eye doctor whether they plan to use IOPIDINE 1% or another pressure-lowering medication to prevent intraocular pressure spikes during the procedure.
• Discuss Your Risk Factors: Tell your doctor about any cardiovascular conditions, recent heart problems, or other health issues, as these may affect which medications are appropriate for you during the procedure.
• Confirm Insurance Coverage: Ask your doctor's office to verify that your insurance will cover IOPIDINE 1% for your specific procedure, especially if your procedure is scheduled after July 1, 2026.
• Understand the Procedure Timeline: Know that the medication is typically administered one hour before the procedure and again immediately after, so plan accordingly for your appointment.

The scale of this change is significant. With more than 4 million Americans living with glaucoma who are regularly seen in clinics, and over 1.5 million ophthalmic laser procedures performed annually in the United States, the removal of reimbursement barriers could mean better outcomes for a large population . Beyond the immediate benefit to patients, preventing pressure spikes also has the potential to reduce overall healthcare costs by minimizing the need for additional follow-up visits, urgent interventions, and the risk of complications that might require more complex procedures down the line .

This regulatory change represents a shift toward making preventive eye care more accessible and practical. When insurance covers a proven, safe medication that prevents serious complications, doctors are more likely to use it consistently, and patients are more likely to receive the protection they need during procedures that affect their vision.